Adaptive Biotechnologies Corporation and Takeda entered into a translational collaboration, utilizing Adaptive’s clonoSEQ Assay to assess minimal residual disease, to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.
Personalis Inc. announced the commencement of commercialization efforts by Tempus for NeXT Personal, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease and recurrence in cancer.
